David Wirta
Ophthalmology · Newport Beach, CANPI 1255435822
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $52,895 of the $59,937 with a category attached, or 88.3%. 17 manufacturers reported payments, led by Alcon at 38.8% of the total. 2025 is the largest year on record at $29,441, 6.9 times the $4,285 reported in 2019. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $936.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$23K
- AbbVie$11K
- Oyster Point Pharma, Inc.$6K
- Mallinckrodt Hospital Products Inc.$6K
- Bausch & Lomb Americas Inc.$4K
- Vertical Pharmaceuticals, LLC$3K
- plus $7K from 11 others
Across 1,026 payments — averaging $18,714 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$10.5M
- Oyster Point Pharma, Inc.$1.6M
- Aerie Pharmaceuticals, Inc.$1.1M
- Alcon Research LLC$1.1M
- Glaukos Corporation$903K
- Novartis$677K
- plus $3.4M from 19 others
What the payments were for
- Consulting fees$52,89588%
- Speaking & faculty fees$3,2005%
- Travel & lodging$2,0673%
- Food & beverage$1,7753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 20 | $23,282 |
| AbbVie(2 entities) | 15 | $10,854 |
| Oyster Point Pharma, Inc. | 3 | $6,215 |
| Mallinckrodt Hospital Products Inc. | 1 | $5,850 |
| Bausch & Lomb Americas Inc. | 2 | $3,877 |
| Vertical Pharmaceuticals, LLC | 1 | $2,750 |
| Dompe US, Inc. | 1 | $2,400 |
| Alcon Research LLC | 3 | $2,382 |
| Aerie Pharmaceuticals, Inc. | 1 | $1,600 |
| Glaukos Corporation | 10 | $381 |
| Kowa Research Institute, Inc. | 1 | $100 |
| Sight Sciences, Inc. | 1 | $90 |
| Thea Pharma Inc. | 1 | $48 |
| Harrow Eye, LLC | 1 | $47 |
| Amgen | 1 | $24 |
| Osmotica Pharmaceutical Corp. | 1 | $24 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,937 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 103 | $765 |
| Timolol Maleate | 43 | $280 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Newport Beach
- Sheri RowenNewport Beach$1M
- Ehsan SadriNewport Beach$255K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.